Any glutamate excess in Alzheimer's may be of glial origin. Aldehydic products of lipid peroxidation apparently inactivate glial glutamate uptake transporters. The correct approach to the problem is at a primary level, by correcting the lipid peroxidation with vitamin E, a measure which renders memantine trials completely unnecessary. Long-chain n-3 EFA are also recommended, to replace the marked oxidative loss of these vital synaptic membrane lipids seen in moderate to advanced disease. Primary prevention of the disease itself will first take place in Australia, where the National Institute of Good Health has plans to produce the world's first vitamin E-replete canola oil on a large scale. No mother using such oil in pregnancy will bear an ADHD child, and neither parent will develop Vegetable Oil Syndrome and eventual fullblown AD.

References:
Peers RJ (1993) Alzheimer's Disease and Vegetable Oils. NZ Med J, 106;481

View all comments by Robert Peers

I read this article in NEJM. Today , is necessary clear some aspects related to aproval by FDA in USA.In EU approved.

References:
NEJM april 2003

View all comments by Armenio Farias

If memantine was helpful in Germany for over 10 years, then the FDA should speed up its approval for use in the US for Alzheimer's disease. Memantine had no side effects in Germany so how can it have side effects in the US? Let's make memantine available for Alzheimer's patients in the US.

View all comments by dale ARATA

What can we do to hurry FDA along? I have sent this info to my Congressman and we are also exploring direct importation.

View all comments by Tom Cofer

If you are looking for this drug, it might be available for import with the help of your doctor or you can also get a British doctor to prescribe it through an online pharmacy.

View all comments by Christina Anagnost